Latest From Antengene Corp.
Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter.
Biopharma investor sentiment plunged at the end 2018, but soared as the J.P. Morgan Healthcare Conference kicked off with another big company acquisition and as industry participants indicated their optimism about financing and deal-making opportunities in 2019.
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.
- Therapeutic Areas
- Infectious & Viral Diseases
- Company Type
- Parent & Subsidiaries
- Antengene Corp.
- Senior Management
Jay Mei, MD, PhD, CEO
Hans de Haan, MD, PhD, CMO
- Contact Info
Phone: 21 3250 1095
Ste. 704, 999 West Zhongshan Rd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.